Show threadCory DoctorowNov 23, 2023

Here's the latest example to cross my path: the #FTC has intervened in a lawsuit over generic insulin pricing, on an issue that is incredibly technically specific and also fantastically important:

https://www.fiercepharma.com/pharma/ftc-blasts-pharmas-abuse-fda-patent-system-sanofi-mylans-insulin-monopoly-lawsuit

The underlying case is before the FDA, and it concerns the dirty tricks that pharma giant #Sanofi used to keep #Mylan from making a generic version of Mylan's #Lantus insulin after its patent expired.

17/

With filing in Sanofi and Mylan insulin lawsuit, FTC amps up scrutiny on pharma's patent tactics

The U.S. Federal Trade Commission (FTC) isn’t letting up in its effort to crack down on pharma’s alleged misuse of a patent mechanism in the FDA’s regulatory process. | The U.S. Federal Trade Commission isn't letting up in its effort to crack down on pharma's alleged misuse of a patent mechanism in the FDA's regulatory process. And it's Sanofi’s turn to land in the crosshairs.

Fierce Pharma
Show threadMoonfirePDXNov 15, 2022
@rbreich While I absolutely agree with the sentiment of this post and the comments about how it should be free as it is required for a large part of the population to literally continue to exist, I'm a bit confused by your definition of "unit", which format of #insulin you're talking about, and where you're getting your data. I'm owned by a #diabetic #cat, so I have the misfortune of paying out-of-pocked prices for insulin. We recently switched from #Lantus to #Semglee, cheaper and biosimilar.